Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Pharming  /  Pharming meldt positieve resultaten Rhucin-te

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,881 19 apr 2024 17:35
  • +0,013 (+1,50%) Dagrange 0,869 - 0,889
  • 8.926.686 Gem. (3M) 6,9M

Pharming meldt positieve resultaten Rhucin-te

73 Posts
Pagina: 1 2 3 4 »» | Laatste | Omlaag ↓
  7. forum rang 10 voda 16 juni 2008 16:41
    HOPPA!!!

    aand. Pharming Group
    Laatste Volume Tijd
    Laatste 0,98 250 16:41:05
    Verschil 0,25 34,2466 %
    Bied 0,95 941 16:41:06
    Laat 0,98 7.265 16:41:06
    Hoogste 0,98 16:40:00
    Laagste 0,72 10:01:10
    Cum. volume --- 970.765 16:41:05
    Indicatieve opening ---
    Open 0,73 09:00:04
    Vorig slot 0,73 13-06-2008
    Gemiddelde dagomzet --- 868.387

  11. forum rang 10 voda 16 juni 2008 16:46
    aand. Pharming Group
    Laatste Volume Tijd
    Laatste 0,99 10.000 16:45:58
    Verschil 0,26 35,6164 %
    Bied 0,98 19.595 16:46:02
    Laat 0,99 12.000 16:46:02
    Hoogste 0,99 16:45:04
    Laagste 0,72 10:01:10
    Cum. volume --- 1.165.351
    Indicatieve opening ---
    Open 0,73 09:00:04
    Vorig slot 0,73 13-06-2008
    Gemiddelde dagomzet --- 868.387

  13. forum rang 10 voda 16 juni 2008 16:48
    aand. Pharming Group
    Laatste Volume Tijd
    Laatste 1,05 6.639 16:46:42
    Verschil 0,32 43,8356 %
    Bied mkt 3.000 16:47:27
    Laat 1,10 20.150 16:47:27
    Hoogste 1,05 16:46:40
    Laagste 0,72 10:01:10
    Cum. volume --- 1.335.341 16:46:42
    Indicatieve opening ---
    Open 0,73 09:00:04
    Vorig slot 0,73 13-06-2008
    Gemiddelde dagomzet --- 868.387

  15. forum rang 10 voda 16 juni 2008 16:50
    Tjakka!

    aand. Pharming Group
    Laatste Volume Tijd
    Laatste 1,08 200 16:50:07
    Verschil 0,35 47,9452 %
    Bied 1,07 5.000 16:50:08
    Laat 1,08 17.376 16:50:08
    Hoogste 1,08 16:50:04
    Laagste 0,72 10:01:10
    Cum. volume --- 1.450.315 16:50:07
    Indicatieve opening ---
    Open 0,73 09:00:04
    Vorig slot 0,73 13-06-2008
    Gemiddelde dagomzet --- 868.387

  17. Doniss 16 juni 2008 16:52
    Pharming Announces Positive Results From North American Randomized Trial With Rhucin®
    Company to move forward with regulatory filings

    Leiden, The Netherlands, June 16, 2008. Biotech company Pharming Group N.V. (“Pharming” or “the Company”) (NYSE Euronext: PHARM) announced today positive safety and efficacy results from its North American trial with Rhucin® (recombinant human C1 inhibitor) for the acute treatment of Hereditary Angioedema (HAE). The positive results with both primary and secondary endpoints of study allow Pharming to move forward with regulatory filings for Rhucin®.

    The randomized double-blind placebo-controlled study with Rhucin® was conducted at several sites in the US and Canada. On having an acute HAE attack, 39 patients were randomized to one of two doses of Rhucin® (100 U/kg, 50 U/kg) or placebo. For the primary endpoint, the intent-to-treat analysis demonstrates that patients who received the 100 U/k! g dose of Rhucin® reported median first symptom relief at approximately 68 minutes, those that received the 50 U/kg dose reported relief at approximately 100 minutes, and those that received placebo reported symptom relief at approximately 258 minutes. The time to minimal clinical symptoms, the secondary endpoint, was reported by patients in the 100 U/kg, 50 U/kg, placebo groups as approximately 245, 247, and 1098 minutes, respectively. The primary and secondary endpoint results with both doses of Rhucin® were clinically meaningful and statistically significant relative to placebo with p-values < 0.01. There was no statistically significant difference observed between patients treated with 100 U/kg or 50 U/kg dose of Rhucin®.

    The North American randomized results with Rhucin® are in line with the positive results from the European randomized placebo-controlled Phase III clinical trial reported previously. The safety experience from the trial indicates that Rhuci! n® continues to be very well tolerated and no relevant, treatment-rel ated adverse events were reported in any of the three treatment groups. Preliminary data from the ongoing open-label phase of the study, including treatment of over 100 attacks, further demonstrates that Rhucin® is safe and effective when treating patients for HAE attacks on a repeated basis. Data on treating repeat attacks represents an important addition to the database and will strengthen upcoming filings. The full results of the open label studies in the US and EU will be reported separately.

    “Rhucin® is the only recombinant human C1 inhibitor product in development for HAE patients and has now unequivocally demonstrated fast acting efficacy in two independent randomized controlled trials,” said Bruno Giannetti MD, PhD, Chief Operations Officer of Pharming. “The safety profile of the recombinant product is also excellent and has been confirmed in several clinical trials involving over 100 subjects with over 200 infusions. We wish to thank all the patient! s as well as investigators for their support in these trials and look forward to providing them a much needed treatment.”

    “The results from the US study demonstrate Rhucin®’s excellent efficacy and safety profile in treating acute attacks of HAE,” said Bruce Zuraw, MD, Professor of Medicine at the University of California San Diego and Principal Investigator of the North American trial. “Having a recombinant human C1 inhibitor protein, such as Rhucin®, as a treatment option for HAE is a notable advance in the field that will be important to both patients and physicians.”

    Based on these results, Pharming intends to file regulatory submissions for Rhucin® in several early launch markets in the second half of 2008 and will meet with EMEA and FDA to accelerate regulatory filings in Europe and the USA.

    About Pharming Group NV
    Pharming Group NV is developing innovative products for the treatment of genetic disorders, aging diseases! , specialty products for surgical indications, intermediates for vario us applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema and human lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via DNage BV). Additional information is available on the Pharming website, www.pharming.com and on www.dnage.nl.
73 Posts
Pagina: 1 2 3 4 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Logische herfinanciering Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. 19 apr Pharming lost voor 123 miljoen euro aan obligaties af
  2. 18 apr Pharming rondt plaatsing obligaties af 5
  3. 18 apr Pharming vervangt converteerbare lening 6
  4. 08 apr Pharming rondt rekrutering voor klinische studie leniolisib met kinderen af
  5. 14 mrt CEO: Pharming haalt omzet uit steeds meer landen 2
  6. 14 mrt Lichte plus voor AEX voorzien; zullen Pharming en Basic-Fit de boel opschudden?
  7. 14 mrt Pharming rekent ook voor 2024 op dubbelcijferige omzetgroei 2
  8. 13 mrt Slotcall: Twijfel slaat toe bij chippers, AEX sluit iets lager na wispelturige sessie
  9. 11 mrt Beursblik: hogere jaaromzet Pharming verwacht
  10. 11 mrt AEX gaat opnieuw rode opening tegemoet, Japan ontloopt recessie maar Nikkei duikelt 1

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!